Legend Biotech, a leading global cell therapy company, has announced the forthcoming presentation of new and updated data from its CARTITUDE clinical development program at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2024 European Hematology Association’s (EHA) Hybrid Congress.
The data from Cohort D of the Phase 2 CARTITUDE-2 study, which examines a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) with or without lenalidomide maintenance in patients who achieved less than complete response after autologous stem cell transplant (ASCT) frontline therapy, will be presented for the first time in an oral presentation at ASCO and in an encore oral presentation at EHA.
Additionally, findings from the subgroup analysis of the Phase 3 CARTITUDE-4 study, comparing CARVYKTI® against two standard therapies in patients with functional high-risk multiple myeloma after one prior line of treatment, will be presented orally at ASCO. Furthermore, the results of the CARTITUDE-4 subgroup analysis by cytogenetic risk will be shared at EHA in a poster session.
Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech, expressed enthusiasm about the forthcoming presentations, stating, “The results of the CARTITUDE clinical development program with CARVYKTI will provide significant insights about the broad range of patients who will benefit from this one-time treatment. We are excited to share our latest data with the hematology and oncology communities as we work to give new hope to patients and strive to one day develop a cure for multiple myeloma.”
The ASCO presentations scheduled from May 31 to June 4, 2024, include:
- Abstract #7504 Oral Presentation: “Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis”
- Abstract #7505 Oral Presentation: “Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in patients with multiple myeloma who had suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D”
- Abstract #7535 Poster: “Ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma: CARTITUDE-2 cohort A expansion subgroup”
The EHA presentations scheduled from June 13 to 16, 2024, include:
- Abstract #S205 Oral Presentation: “Encore: Ciltacabtagene autoleucel ± lenalidomide maintenance in patients with multiple myeloma who had suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D”
- Abstract #P959 Poster: “Encore: Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis”
- Abstract #P978 Poster: “Ciltacabtagene autoleucel vs standard of care in lenalidomide-refractory multiple myeloma: Phase 3 CARTITUDE-4 subgroup analysis by cytogenetic risk”
- Abstract #P967 Poster: “Comparative effectiveness of ciltacabtagene autoleucel from the CARTITUDE-4 trial vs real-world physician’s choice of therapy from the flatiron registry in lenalidomide-refractory multiple myeloma”
- Abstract #P863 Poster: “Clinical biomarkers associated with progression free survival to ciltacabtagene autoleucel in Chinese patients with relapsed/refractory multiple myeloma from CARTIFAN-1 STUDY”
